# Irritable Bowel Syndrome (IBS) **Prepared by:** Pedro Cheung MD **Last Updated:** May 2026 ## A Comprehensive Guide for Patients _Based on current evidence, ACG/AGA clinical guidelines, and peer-reviewed literature as of May 2026_ --- ## What Is IBS? Irritable Bowel Syndrome (IBS) is one of the most common gastrointestinal (GI) conditions in the world, affecting an estimated **10–15% of adults** globally. Despite its prevalence, it is frequently misunderstood — both by patients and, historically, by the medical community. IBS is **not** simply "a nervous stomach," a sign of anxiety, or a problem that can be cured by relaxing. It is a real, biologically grounded condition that causes significant suffering and meaningfully reduces quality of life. IBS belongs to a category now called **Disorders of Gut-Brain Interaction (DGBI)** — a name that recognizes what modern research has confirmed: the condition arises from complex, bidirectional disruptions between the brain, the nervous system of the gut, the immune system, and the microbiome. It is not a structural disease (no anatomical abnormality can be seen on a scope or scan), but that does not make it less real. The biology driving IBS is measurable, reproducible, and the subject of intense ongoing research. IBS imposes a major economic burden: patients spend an estimated **$742 to $7,547 per year** in direct healthcare costs, and it accounts for a significant proportion of all gastroenterology visits in the United States.[^1] ### Key Facts at a Glance - IBS affects roughly 1 in 10 adults; women are diagnosed about **twice as often** as men[^2] - It most commonly begins between ages 18 and 45 - IBS does **not** increase the risk of colon cancer, inflammatory bowel disease (IBD), or other serious GI diseases - It is often associated with anxiety, depression, and fibromyalgia — conditions that share overlapping biological pathways - Effective treatments exist for every subtype — but IBS requires a personalized, multimodal approach - IBS has official ICD-10-CM diagnostic codes: **K58.0** (with diarrhea), **K58.1** (with constipation), **K58.2** (mixed), **K58.9** (unspecified)[^3] --- ## What Is Happening Inside Your Body? For decades, IBS was described simply as a motility disorder. We now know the condition is far more complex, involving at least six major interacting biological systems. Understanding these mechanisms can help you understand _why_ your symptoms occur — and why different treatments target different aspects of the same disease.[^4][^5] ### 1. The Gut-Brain Axis: A Two-Way Highway Gone Wrong The most fundamental change in our understanding of IBS is the recognition that the gut and brain are in constant bidirectional communication — and that this communication is disrupted in IBS. Your gut contains its own nervous system, the **Enteric Nervous System (ENS)**, sometimes called the "second brain." The ENS communicates constantly with the Central Nervous System (brain and spinal cord) through neural, hormonal, and immune pathways. This network — the gut-brain axis — regulates motility, secretion, sensation, and immune responses throughout the GI tract. In IBS, this axis is dysregulated. Signals traveling from the gut to the brain are misread or amplified; signals from the brain to the gut produce abnormal responses. Stress activates the **hypothalamic-pituitary-adrenal (HPA) axis**, releasing cortisol that further disrupts gut motility, increases intestinal permeability, and alters immune function — creating a vicious cycle in which psychological stress and GI symptoms perpetuate each other.[^4][^5] ### 2. Visceral Hypersensitivity: Your Gut's Alarm System Is Set Too Sensitive One of the most consistent and well-documented findings in IBS is **visceral hypersensitivity** — the gut's pain-sensing nervous system is abnormally sensitized. Normal sensations (the movement of gas, mild distension of the colon) that healthy people do not notice are perceived by people with IBS as pain, cramping, or discomfort. This is not imagined pain. It has a measurable biological basis: changes in how pain signals are processed at the peripheral nerve level (in the gut wall), at the spinal cord, and in the brain's processing of GI pain signals. Visceral hypersensitivity explains why even gentle stimulation — a meal, emotional stress, or a small amount of gas — can trigger significant symptoms.[^4][^6] ### 3. Mast Cells and Immune Activation: The Inflammatory Bridge A key recent insight is the role of **mast cells** — immune cells that reside in the gut wall, positioned immediately adjacent to the nerve endings that sense pain. In IBS, mast cells are abnormally activated, releasing a cocktail of inflammatory mediators — primarily **histamine** and **tryptase** — directly onto these pain-sensing nerves. This histamine release activates a nerve receptor called **TRPV1**, which directly sensitizes gut afferent neurons and amplifies visceral pain signals. Mast cell activation in IBS is triggered by food antigens (through local IgE-mediated reactions), psychological stress, and prior infections. This discovery has led to targeted clinical trials of antihistamines and mast cell stabilizers as novel IBS treatments.[^7][^8] **Low-grade inflammation** in the gut mucosa also contributes to IBS. This is not the severe, tissue-damaging inflammation of Crohn's disease or ulcerative colitis, but it is detectable: elevated mucosal immune cells (eosinophils, intraepithelial lymphocytes), elevated cytokines, and evidence of immune activation that correlates with symptom severity.[^4] ### 4. The Gut Microbiome: When Your Inner Ecosystem Is Out of Balance Your GI tract contains trillions of microorganisms — bacteria, fungi, viruses — that collectively form the **gut microbiome**. In health, this ecosystem regulates immune function, produces neurotransmitters (including serotonin and GABA), maintains the gut lining's barrier function, and produces short-chain fatty acids (SCFAs, especially butyrate) that feed the colon's lining cells. In IBS, the microbiome is disrupted in reproducible ways — a state called **dysbiosis**. Characteristic findings include reduced bacterial diversity, lower levels of beneficial bacteria (Bifidobacteria, Faecalibacterium prausnitzii, Lactobacillus), and higher levels of pro-inflammatory species. Reduced butyrate production impairs gut barrier integrity and immune regulation. Altered bile acid metabolism is particularly important in IBS-D, where excess bile acids reaching the colon accelerate gut motility and cause diarrhea.[^9][^10] IBS patients also have distinct dysregulation of the **tryptophan-serotonin-kynurenine pathway** — the metabolic chain through which the gut produces serotonin (5-HT), the neurotransmitter that controls approximately 95% of gut motility and secretion. Abnormal serotonin signaling is a core driver of both the motility disturbances and sensory abnormalities of IBS.[^5] ### 5. Intestinal Barrier Dysfunction: When the Wall Develops Gaps The gut lining acts as a selective barrier — it absorbs nutrients and water while blocking bacteria and inflammatory molecules from crossing into the bloodstream. In IBS, this barrier is compromised, with measurable increases in gut permeability (often called "leaky gut"). Increased permeability allows bacteria and their products to stimulate the mucosal immune system, sustaining the low-grade inflammation and immune activation described above, and contributing to visceral hypersensitivity.[^4][^5] ### 6. Altered Bowel Motility and Transit Disrupted communication along the gut-brain axis produces abnormal patterns of gut muscle contractions. In IBS-C, contractions are too slow (constipation, bloating, hard stools). In IBS-D, contractions are too fast (urgency, loose stools, incomplete evacuation). In IBS-M, these patterns alternate. Bile acid malabsorption contributes specifically to IBS-D by dramatically accelerating colon transit when excess bile acids reach the large intestine.[^4] ### What Causes IBS? Risk Factors and Triggers IBS is multifactorial — there is no single cause. Multiple factors interact to produce the disorder: |Risk/Trigger Factor|What We Know| |---|---| |**Post-infectious IBS**|Risk of developing IBS is **6 times higher** after an acute GI infection (gastroenteritis). Post-infectious IBS may account for 5–32% of all IBS cases[^4]| |**Psychological stress**|Stress activates the HPA axis and directly alters gut motility, microbiome composition, and visceral sensitivity| |**Antibiotic use**|Disrupts the gut microbiome; may trigger or worsen IBS, especially in predisposed individuals| |**Sex and hormones**|Women are twice as likely to be diagnosed; hormonal fluctuations (menstrual cycle) frequently worsen symptoms| |**Early-life adversity**|Trauma, abuse, or adverse childhood experiences are associated with altered HPA programming and higher IBS risk| |**Genetic susceptibility**|Family history increases risk; genome-wide studies have identified variants in immune and nervous system genes| |**Dietary factors**|High-FODMAP foods, alcohol, caffeine, and fatty foods are common symptom triggers in predisposed individuals| --- ## Common Symptoms and Subtypes IBS is defined by two core features that must be present together: **recurrent abdominal pain** AND **changed bowel habits**. The character of those bowel changes defines the subtype. ### The Four IBS Subtypes (Rome IV) |Subtype|Code|Pattern| |---|---|---| |**IBS-C** (Constipation-predominant)|K58.1|Hard or lumpy stools (Bristol Type 1–2) predominate| |**IBS-D** (Diarrhea-predominant)|K58.0|Loose or watery stools (Bristol Type 6–7) predominate| |**IBS-M** (Mixed)|K58.2|Both hard and loose stools occur| |**IBS-U** (Unclassified)|K58.9|Does not fit the above patterns| ### Symptom Overview |Symptom Category|What Patients Experience| |---|---| |**Abdominal pain**|Cramping, aching, or sharp pain; often improves with bowel movements; frequently in the lower abdomen| |**Bloating and distension**|Visible abdominal swelling; sense of gas or fullness; often worsens through the day| |**Stool changes**|Urgency, frequency changes, straining, incomplete evacuation, mucus in stool| |**Extraintestinal symptoms**|Fatigue, fibromyalgia, bladder urgency, headaches, back pain — reflecting shared pathways| |**Psychological**|Anxiety and depression are significantly more common in IBS; each worsens the other| ### When to See Your Doctor Promptly (Alarm Features) The following symptoms should prompt prompt medical evaluation, as they may indicate conditions other than IBS that require further testing: - Rectal bleeding or blood in stool - Involuntary weight loss - Nocturnal diarrhea (waking at night to have a bowel movement) - Fever or chills - A palpable abdominal mass - New onset after age 50 with no prior GI history - Family history of colorectal cancer, IBD, or celiac disease --- ## How Is IBS Diagnosed? IBS is diagnosed using **Rome IV criteria** — a positive diagnosis based on your symptom pattern, not solely by ruling out other diseases. This approach is now strongly recommended by both the American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) because it is accurate, reduces unnecessary testing, and gets you to treatment faster.[^11][^12] ### The Rome IV Diagnostic Criteria All of the following must be present: **Recurrent abdominal pain, on average at least 1 day per week in the last 3 months**, associated with **two or more** of the following: 1. Related to defecation (pain improves or worsens with bowel movements) 2. Associated with a change in stool frequency 3. Associated with a change in stool form (appearance) Symptoms must have begun at least **6 months ago** and been active for at least the past **3 months**. ### Tests Your Doctor Should Order |Test|Purpose| |---|---| |**Celiac disease serology** (tTG-IgA)|Rule out celiac disease — which mimics IBS and affects ~1% of the population[^11]| |**Fecal calprotectin**|A stool biomarker used to **rule out IBD in patients without alarm features** — a normal result makes IBD very unlikely and confirms the IBS diagnosis. (Note: if alarm features ARE present, direct colonoscopy is preferred over stool biomarkers)[^11]| |**CBC, metabolic panel, thyroid**|Rule out anemia, thyroid disease, electrolyte issues| |**Colonoscopy**|Reserved for patients with alarm features, age >50, or strong family history| A positive diagnosis of IBS can be made when Rome IV criteria are met, celiac and IBD have been excluded, and no alarm features are present. Normal test results are expected in IBS and do not mean your symptoms aren't real. --- ## Non-Pharmacological Treatments (The Foundation of Care) Lifestyle and dietary interventions are the **foundation** of IBS management — and recent evidence shows they can be more effective than medications for many patients. The 2024 CARBIS trial (Lancet Gastroenterology & Hepatology), the largest dietary RCT for IBS to date, found that both dietary interventions outperformed optimized pharmacotherapy at 4 weeks (76% and 71% vs. 58% response rates, respectively).[^13] --- > ⚠️ **IBS treatment is not one-size-fits-all.** The most effective approach combines dietary change, lifestyle modification, and (when needed) behavioral therapies and/or medication — tailored to your subtype and symptom severity. --- ### 1. Dietary Therapy: The Most Validated First-Line Treatment #### The Low-FODMAP Diet: The Gold Standard Dietary Intervention FODMAPs are **F**ermentable **O**ligo-, **D**i-, **M**onosaccharides **A**nd **P**olyols — a group of short-chain carbohydrates that are poorly absorbed in the small intestine. When they reach the large intestine, gut bacteria ferment them, producing gas, water, and distension — directly triggering IBS symptoms in susceptible individuals. The low-FODMAP diet is the most rigorously studied dietary intervention for IBS, with **50–80% of patients experiencing significant symptom reduction**.[^13][^14] **CRITICAL: The low-FODMAP diet is a three-phase process — it is NOT a lifelong diet.** Staying in the strict elimination phase indefinitely is actively discouraged because it deprives beneficial gut bacteria of their food source, worsening the microbiome dysbiosis that underlies IBS. The three phases are: **Phase 1 — Elimination (4–6 weeks):** Strictly avoid all high-FODMAP foods. Common high-FODMAP foods include wheat, rye, cow's milk, onions, garlic, apples, pears, stone fruits (peaches, cherries), legumes, and certain sweeteners (fructose, sorbitol, mannitol). The goal is to achieve symptom remission. **Phase 2 — Structured Reintroduction (6–8 weeks):** Systematically reintroduce individual FODMAP groups, one at a time, in test portions, while monitoring symptoms. This identifies your specific personal triggers. Not everyone reacts to all FODMAP groups — most people tolerate several of them. A 2024 RCT confirmed that fructans and mannitol are the most common individual triggers, but responses are highly personalized.[^15] **Phase 3 — Personalization (ongoing):** A relaxed, individualized long-term eating pattern that avoids only your identified triggers. This is more nutritionally balanced, easier to maintain, and protects your gut microbiome. **Important practical notes about the low-FODMAP diet:** - It is complex and best implemented with guidance from a trained GI dietitian - It is more effective in patients with more severe baseline symptoms[^14] - Individual FODMAP thresholds vary — many people can tolerate small amounts of trigger foods - Long-term compliance in the elimination phase risks nutritional deficiencies and worsened microbiome diversity #### The Low-Carbohydrate Diet: A Simpler Alternative The 2024 CARBIS trial established that a fiber-optimized **low-carbohydrate diet** (high protein, high fat) was nearly as effective as low-FODMAP at 4 weeks (71% vs. 76% response rate) and may be easier for many patients to follow because it does not require the complex three-phase FODMAP protocol.[^13] This diet is a valid first-line option, particularly for patients who find the FODMAP approach too burdensome. #### The Mediterranean Diet: Emerging Evidence for Long-Term Health A 2024 network meta-analysis of 23 RCTs ranked the **Mediterranean diet** as the highest-ranked dietary intervention for improving IBS Symptom Severity Scores (IBS-SSS) and quality of life among the approaches studied.[^16] The Mediterranean diet's anti-inflammatory properties may address underlying immune activation in IBS in ways that exclusion diets alone do not. A Mediterranean low-FODMAP hybrid diet is currently under investigation in an RCT (NCT03997708) and may prove to be an optimal combined strategy. #### Traditional IBS Dietary Advice (NICE Guidelines) Standard evidence-based dietary advice includes regular meals, adequate hydration, reduced caffeine/alcohol/carbonated beverages, and reduction of processed/high-fat foods. This approach is less restrictive, more accessible, and in some studies showed comparable efficacy to low-FODMAP — making it a reasonable starting point, especially in milder IBS.[^17] #### Dietary Fiber: A Critical Distinction Soluble, non-fermentable fiber — especially **psyllium** — is recommended as a first-line therapy for IBS-C. It softens stool without excessive gas production. Insoluble fiber (wheat bran) may worsen bloating and is generally not recommended. Fermentable fibers (found in legumes and oats) are restricted in the FODMAP elimination phase because they produce gas.[^18] #### Foods to Avoid for Most IBS Patients - High-FODMAP foods (during elimination phase): garlic, onions, wheat, rye, apples, pears, cow's milk, most legumes - Fatty or greasy meals (stimulate gut contractions) - Caffeine (accelerates transit; can trigger IBS-D) - Carbonated beverages (increase gas and bloating) - Alcohol (irritates the GI lining and disrupts microbiome) - Sugar alcohols (sorbitol, mannitol, xylitol) — found in many sugar-free products ### 2. Soluble Fiber Supplementation For IBS-C specifically, **psyllium husk** (Metamucil) at 10–20g per day with plenty of water is a simple, inexpensive, and effective first step to relieve constipation and improve overall symptoms. Ensure adequate hydration — fiber without water worsens constipation.[^18] ### 3. Cognitive Behavioral Therapy (CBT): Highly Effective Mind-Gut Treatment CBT for IBS is not psychological treatment for a "psychological" problem. It directly addresses the dysfunctional gut-brain communication patterns that drive IBS symptoms. CBT teaches patients to identify and modify thought patterns that amplify GI sensations, reduce GI-specific anxiety, and change behavioral responses to symptoms. Multiple systematic reviews confirm CBT as an effective treatment for IBS, with durable long-term benefit. It is particularly effective for patients with significant GI anxiety, stress-triggered symptoms, or when medication alone has been insufficient.[^1][^19] Recent advances have made CBT more accessible: - **Group CBT** is effective and reduces cost barriers - **Digital/web-based CBT** programs show promise in early RCTs - **CBT delivered by nurse practitioners** demonstrated effectiveness in preliminary studies The ACG recommends gut-directed psychotherapy in its 2021 guidelines.[^11] ### 4. Gut-Directed Hypnotherapy: An Evidence-Based Approach Gut-directed hypnotherapy (GDH) uses hypnotic techniques to directly calm the enteric nervous system and reduce visceral hypersensitivity. It is one of the most effective psychological therapies for IBS and is formally recommended by the ACG. A 2021 RCT confirmed that **6 sessions of GDH are non-inferior to 12 sessions**, making it significantly more accessible.[^1] Sessions typically combine education about the gut, relaxation induction, and personalized gut-calming imagery. Patients learn self-hypnosis techniques to use between sessions. ### 5. Exercise and Physical Activity Regular physical activity has a well-documented positive effect on IBS symptoms, including improvements in abdominal pain, bloating, and quality of life. A 2023 RCT in the American Journal of Gastroenterology confirmed that both **meditation/yoga** and structured exercise were effective in reducing IBS severity.[^1] Exercise also improves gut microbiome diversity, reduces anxiety (which perpetuates the gut-brain cycle), and normalizes gut transit. **Recommended:** 30 minutes of moderate-intensity exercise (walking, swimming, cycling) 5 days per week. Even short daily walks are beneficial. Yoga has specific evidence for IBS. ### 6. Stress Management and Sleep Psychological stress is one of the most potent triggers of IBS flares through its direct effects on the gut-brain axis. Chronic stress maintains the state of visceral hypersensitivity and alters gut microbiome composition. Evidence-based stress management strategies include: - Mindfulness-based stress reduction (MBSR) - Diaphragmatic breathing exercises - Progressive muscle relaxation - Adequate sleep hygiene (7–9 hours per night; consistent sleep-wake times) - Reduction of excessive workload and burnout ### 7. Keeping a Symptom and Food Diary A 2-week symptom and food diary is one of the most practical tools for identifying personal triggers, understanding your symptom patterns, and guiding dietary personalization. Record: meals eaten, stress levels, sleep quality, bowel habits (using the Bristol Stool Form Scale), and pain scores. Share the diary with your doctor or dietitian. --- ## Pharmacological Treatments There is no single medication that cures IBS. However, multiple medications are FDA-approved or guideline-recommended for specific IBS subtypes, and significant progress has been made in the last few years in establishing their safety profiles. The 2025 safety meta-analysis in the American Journal of Gastroenterology (Busam et al., 54 trials) found that **rifaximin** has the most favorable safety profile of any pharmacotherapy studied for IBS.[^20] > **"Start low, go slow"** — many IBS patients are sensitive to medications, particularly neuromodulators. Start at the lowest effective dose and increase gradually. --- ### Treatments for IBS-C (Constipation-Predominant) #### Over-the-Counter First Steps **Polyethylene glycol (PEG, Miralax)** — an osmotic laxative that draws water into the colon. It reliably improves bowel frequency and stool consistency in IBS-C. Note: the ACG advises that PEG does not significantly improve abdominal pain (the core IBS symptom), so it is most useful when constipation is the predominant complaint alongside pain.[^1] #### Prescription Secretagogues: The Most Effective IBS-C Drugs These medications work by stimulating the gut to secrete fluid into the intestinal lumen, softening stool and — importantly — also reducing visceral pain through direct nerve effects. **Linaclotide (Linzess) — Strongest Evidence** Linaclotide is a guanylate cyclase-C (GC-C) receptor agonist. It is the most evidence-supported medication for IBS-C, earning a **strong recommendation** from the ACG (high certainty of evidence) — the highest grade in the IBS guideline. It reduces both abdominal pain and constipation simultaneously, with a **number needed to treat (NNT) of 7**.[^11][^12] The most common side effect is diarrhea (in 16% of patients), which can usually be managed by adjusting timing (taking it 30–60 minutes before breakfast). Standard IBS-C dose: 290 mcg once daily. **Plecanatide (Trulance)** A similar GC-C agonist to linaclotide with comparable efficacy. A conditional AGA recommendation (moderate certainty). Main side effect is also diarrhea. May be better tolerated in patients who experience dose-limiting diarrhea with linaclotide.[^12] **Tenapanor (Ibsrela)** A sodium/hydrogen exchanger 3 (NHE3) inhibitor — a novel mechanism that reduces intestinal sodium absorption, increasing water secretion into the colon. Approved for IBS-C. Effective for both pain and constipation. The NNH for treatment discontinuation due to adverse events (primarily diarrhea) is 16 — the least favorable in the IBS-C drug class.[^20] **Lubiprostone (Amitiza)** Activates chloride channels to increase intestinal fluid secretion. Effective for IBS-C; AGA conditional recommendation. Most common side effects: nausea (mitigated by taking with food) and diarrhea. **Tegaserod (Zelnorm)** A serotonin 5-HT4 receptor partial agonist that accelerates GI transit. FDA-approved for IBS-C in **women under 65 without cardiovascular disease or risk factors** (no history of heart attack, stroke, TIA, or angina). Note: despite FDA reapproval in 2019, tegaserod is currently unavailable commercially in the U.S. for reasons unrelated to safety. --- ### Treatments for IBS-D (Diarrhea-Predominant) #### Over-the-Counter First Step **Loperamide (Imodium)** — a peripheral mu-opioid agonist that slows gut motility and reduces stool frequency. It is effective at improving diarrhea and stool consistency, and the AGA conditionally recommends it for IBS-D. One important nuance: loperamide does not treat abdominal pain or global IBS symptoms — it addresses the diarrhea component only.[^1] #### Prescription Options **Rifaximin (Xifaxan) — Safest and Most Widely Recommended** A non-absorbable antibiotic that targets gut bacteria without entering the bloodstream, directly addressing the microbial dysbiosis component of IBS-D. Approved for a 14-day treatment course; can be retreated if symptoms recur. Both the ACG (strong recommendation) and AGA (conditional, moderate certainty) recommend it. The 2025 safety meta-analysis of 54 trials confirmed rifaximin has the most favorable safety profile of any IBS pharmacotherapy — participants taking rifaximin actually had a lower discontinuation rate than placebo.[^20] Improves abdominal pain, bloating, and stool consistency. **Eluxadoline (Viberzi)** A peripherally acting mixed opioid agonist/antagonist (mu + kappa agonist, delta antagonist) that reduces gut motility and visceral pain. Effective for both diarrhea and pain in IBS-D. ACG and AGA conditional recommendations. ⚠️ **Important contraindications:** Eluxadoline significantly increases the risk of pancreatitis in certain patients. It must **not** be used in patients who: - Have had their gallbladder removed (cholecystectomy) - Drink more than 3 alcoholic beverages per day - Have a history of alcohol use disorder, pancreatitis, or liver disease **Alosetron (Lotronex)** A highly selective 5-HT3 serotonin receptor antagonist. Effective for severe IBS-D in women — particularly the subset with urgency, frequency, and significant pain that has not responded to other therapies. Due to a risk of ischemic colitis and severe constipation complications, alosetron is restricted in the U.S. to **women only**, under a Risk Evaluation and Mitigation Strategy (REMS) program requiring prescriber enrollment.[^1] Reserved for severe, refractory IBS-D. **Ondansetron (Zofran) — Emerging Evidence** A 5-HT3 antagonist (the same class as alosetron) commonly used for nausea, now showing RCT evidence for IBS-D. A 2023 RCT (the TRITON trial) and a 2020 phase 2 RCT both demonstrated improvement in stool consistency and overall symptoms in IBS-D patients of both sexes. Not yet in ACG/AGA guidelines; ask your gastroenterologist.[^1] **Bile Acid Sequestrants (Cholestyramine, Colesevelam)** For IBS-D patients whose symptoms are driven by bile acid malabsorption (BAM) — a subset estimated at 25–50% of IBS-D cases — bile acid sequestrants that bind and remove excess bile acids from the colon can provide significant relief. These include cholestyramine (Questran) and colesevelam (Welchol). They are inexpensive, well-established, and represent an important option for patients who have not responded to first-line IBS-D therapies. Testing for BAM (SeHCAT scan, or empiric trial) should be considered in refractory IBS-D.[^11] --- ### Treatments for Global Symptoms (All Subtypes) #### Neuromodulators / Gut-Brain Modulators **Low-Dose Tricyclic Antidepressants (TCAs) — ACG Strong Recommendation** TCAs at doses used for IBS (typically **10–30 mg/day**) are not being prescribed as antidepressants — they are being used as **gut-brain neuromodulators** that work through multiple mechanisms: reducing visceral hypersensitivity, slowing gut transit (useful in IBS-D), and modulating pain processing centrally. This distinction is important — you do not need to have depression to benefit from these drugs for IBS. The ACG issued a strong recommendation for TCAs based on moderate-quality evidence. A recent community-based RCT confirmed that titrated amitriptyline (10–30 mg) for 6 months was significantly superior to placebo for IBS symptom relief.[^11] **Practical notes for patients:** - Take at **bedtime** — TCAs cause sedation, and the sleepiness helps with nighttime dosing - Start at 10 mg; your doctor will increase slowly every 2–4 weeks as tolerated - Common side effects: drowsiness, dry mouth, constipation — usually manageable at these low doses - Allow **4–8 weeks** before judging effectiveness - Secondary amine TCAs (nortriptyline, desipramine) may have fewer side effects than amitriptyline for some patients **Selective Serotonin Reuptake Inhibitors (SSRIs)** Somewhat counterintuitively, SSRIs have **not** been shown to significantly improve global IBS symptoms or abdominal pain in clinical trials. Both the ACG and AGA recommend **against** SSRIs as primary IBS treatment. They may have a role in patients with concurrent significant anxiety or depression, but should not replace established IBS therapies.[^11][^12] #### Antispasmodics Antispasmodics relax smooth muscle in the gut wall, reducing cramping. They include: - **Hyoscine (Levsin/Buscopan)** — anticholinergic; most commonly used - **Dicyclomine (Bentyl)** — anticholinergic - **Mebeverine (Colofac)** — not available in the U.S.; widely used internationally The evidence for antispasmodics is mixed. The ACG recommends **against** their use for global IBS symptoms (low quality evidence). The AGA makes a **conditional recommendation** in favor, with caution in IBS-C patients (anticholinergic side effects can worsen constipation). Antispasmodics work best for short-term, on-demand relief of acute cramping.[^1][^11][^12] #### Peppermint Oil Peppermint oil capsules work as a natural antispasmodic by blocking smooth muscle calcium channels. The ACG recommends peppermint oil for IBS, though some more recent RCTs have shown inconsistent results compared to placebo. ⚠️ **Important warning:** Peppermint oil **relaxes the lower esophageal sphincter** and can cause or worsen heartburn (GERD) and reflux symptoms. It should be avoided by patients with hiatal hernia or GERD. Enteric-coated formulations reduce this risk by preventing peppermint release until the small intestine. --- ### Summary: FDA-Approved and Guideline-Recommended Drugs |Target|Drug(s)|Subtype|Strength of Evidence| |---|---|---|---| |**Secretagogues**|Linaclotide (Linzess)|IBS-C|ACG Strong / AGA Strong| ||Plecanatide (Trulance)|IBS-C|ACG/AGA Conditional| ||Tenapanor (Ibsrela)|IBS-C|AGA Conditional| ||Lubiprostone (Amitiza)|IBS-C|ACG/AGA Conditional| ||Tegaserod (Zelnorm)|IBS-C (women <65)|Conditional; commercially unavailable| |**Microbiome**|Rifaximin (Xifaxan)|IBS-D|ACG Strong / AGA Conditional| |**Motility**|Eluxadoline (Viberzi)|IBS-D|ACG/AGA Conditional| ||Alosetron (Lotronex)|IBS-D severe (women)|Conditional; REMS required| ||Loperamide (Imodium)|IBS-D|AGA Conditional (diarrhea only)| |**Bile acids**|Bile acid sequestrants|IBS-D (BAM-related)|Guideline-supported empiric trial| |**Neuromodulators**|TCAs (amitriptyline, etc.)|All subtypes|ACG Strong / AGA Conditional| ||Antispasmodics|All subtypes|ACG against; AGA Conditional| ||SSRIs|Not recommended|ACG/AGA recommend against| |**Natural**|Peppermint oil|All subtypes|ACG Conditional; caution with GERD| |**Osmotic laxatives**|PEG (Miralax)|IBS-C|AGA Conditional (constipation only)| |**Fiber**|Psyllium (Metamucil)|IBS-C|ACG Conditional| --- ## Emerging and Novel Treatments (2024–2026 Research Highlights) ### Ebastine: A Common Antihistamine Showing Promise for IBS One of the most exciting findings in recent IBS research stems from the discovery that **mast cell-derived histamine** is a key driver of visceral hypersensitivity. A 2024 randomized, double-blind, placebo-controlled Phase 2b trial published in _Gut_ (Decraecker et al., n=202) evaluated **ebastine** — a well-established, widely available second-generation antihistamine — in non-constipated IBS patients. Ebastine (20 mg once daily for 12 weeks) produced significantly more symptom responders than placebo for the composite endpoint of global symptom relief plus reduced abdominal pain (12% vs. 4%, p=0.047).[^7] Symptom improvement accumulated over 6–8 weeks of treatment. A Phase 3 trial comparing ebastine to mebeverine in 200 IBS patients is currently recruiting (NCT05815602, expected completion 2027). If confirmed, this would represent the first truly new class of IBS drug — a widely available, safe, inexpensive antihistamine repurposed for IBS based on its mechanism of blocking histamine-driven visceral pain. ### Mast Cell Stabilizers (Ketotifen, Cromoglycate) Ketotifen and disodium cromoglycate (DSCG) — drugs that stabilize mast cells and prevent their degranulation — have shown benefit in IBS trials. A 2024 systematic review found significant symptom improvement with mast cell-targeted therapies (including ebastine, ketotifen, and DSCG) compared to control, though evidence quality was variable. Larger trials are underway.[^8] ### Microbiome-Personalized Diets Using Artificial Intelligence A 2024 multicenter RCT compared a standard low-FODMAP diet to a microbiome-based AI-assisted personalized diet. Both approaches produced significant symptom improvement, but the AI-assisted personalized diet led to greater microbiome diversity shifts and improvements across all IBS subtypes — suggesting precision dietary medicine may eventually outperform standardized dietary protocols.[^21] ### Fecal Microbiota Transplantation (FMT) FMT — transplanting gut microbiota from a healthy donor — is biologically rational for IBS given the evidence for dysbiosis, and some trials have shown short-term benefit. However, results across multiple RCTs have been mixed, and current evidence does not support FMT as a routine IBS treatment outside of clinical trials. Long-term efficacy appears limited, with symptom return within 3–12 months in most studies. Ongoing trials are investigating FMT for IBS (NCT03613545, NCT07481422).[^1] ### Vitamin D Supplementation A 2024 systematic review and meta-analysis (7 RCTs) found moderate evidence that Vitamin D supplementation improves quality of life in IBS patients who are Vitamin D deficient, though effects on IBS symptom severity were not statistically significant at the group level. Given the high prevalence of Vitamin D deficiency in IBS patients and the favorable safety profile of supplementation, testing Vitamin D levels and correcting deficiency is a reasonable intervention.[^22] --- ## Prognosis: What to Expect IBS is a **chronic but manageable condition** for most patients. It does not shorten life expectancy, does not progress to cancer or serious bowel disease, and does not cause permanent structural damage to the GI tract. The range of outcomes is wide: - Some patients achieve excellent control through dietary changes and/or medication and experience infrequent, mild flares - Many patients have waxing and waning symptoms over years, with good periods and challenging periods - A minority of patients have severe, persistent symptoms despite multiple treatments — these patients benefit most from multidisciplinary care including GI psychology - Spontaneous long-term remission occurs in approximately 30% of patients ### Factors That Improve Outcomes - **Early, accurate diagnosis** — reduces years of unnecessary testing and inappropriate treatments - **Dietary intervention** — consistent management of FODMAP triggers significantly reduces flare frequency - **Addressing psychological comorbidities** — treating concurrent anxiety and depression improves both mental health and GI symptoms - **Multidisciplinary care** — a landmark RCT (the MANTRA trial, Lancet Gastroenterol 2020) found that multidisciplinary care (GI dietitian + GI psychologist + gastroenterologist) was significantly more effective and cost-efficient than gastroenterologist-only care[^1] - **Identifying and treating comorbidities** — including SIBO, BAM, celiac disease, and MCAS ### Reasons for Genuine Optimism The science of IBS has accelerated dramatically in the last decade, driven by improved tools for studying the microbiome, gut-brain interaction, and mucosal immunology. Several promising avenues are currently in Phase 3 trials (ebastine, tenapanor in pediatrics) and the field is moving toward **precision medicine** — matching specific treatments to specific biological subtypes of IBS rather than treating everyone the same way. --- > **A Message to You** > > Your symptoms are real. They have a measurable biological basis in the way your nervous system processes gut signals, the way your immune cells respond to bacteria and food, and the way your brain and gut communicate. IBS is not a sign of weakness, anxiety disorder, or a personality problem. Advocate for yourself with your healthcare team, pursue evidence-based treatments, and know that the landscape of effective options continues to improve every year. --- ## Key References [^1]: Tetali B, Suresh S. Management of irritable bowel syndrome: a narrative review. Translational Gastroenterology and Hepatology. 2024;9:26. https://doi.org/10.21037/tgh-23-96 (PMC11074491) [^2]: Almario CV, et al. Prevalence and Burden of Illness of Rome IV IBS in the United States. Gastroenterology. 2023;165:1475–87. https://doi.org/10.1053/j.gastro.2023.08.010 [^3]: CDC. ICD-10-CM Code K58 – Irritable bowel syndrome. https://www.cdc.gov/me-cfs/hcp/diagnosis/index.html [^4]: Unraveling the Pathophysiology of Irritable Bowel Syndrome: Mechanisms and Insights. PMC12607773. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12607773/ [^5]: Current Insights and Future Directions in IBS. PMC12800576. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12800576/ [^6]: Gut Microbiota in Irritable Bowel Syndrome: A Narrative Review. Frontiers in Immunology. 2025. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1695321/full [^7]: Decraecker L, et al. Treatment of non-constipated IBS with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial. Gut. 2024;73(3):459–469. https://pubmed.ncbi.nlm.nih.gov/38191268/ [^8]: Kips A, et al. Efficacy of mast cell directed therapies in irritable bowel syndrome: a systematic review. Acta Gastroenterol Belg. 2024;87(1):15–27. https://pubmed.ncbi.nlm.nih.gov/38431786/ [^9]: Zhang H, et al. Low-FODMAP Diet for Irritable Bowel Syndrome: Insights from Microbiome. Nutrients. 2025. https://consensus.app/papers/details/92587cf7c64a56939b6ec15a0290154c/ [^10]: Association between the Gut Microbiota and the Pathophysiology of IBS. Digestion. 2026;doi:10.1159/000550907. https://pubmed.ncbi.nlm.nih.gov/41642746/ [^11]: Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:17–44. https://doi.org/10.14309/ajg.0000000000001036 [^12]: Chang L, Sultan S, Lembo A, et al. AGA Clinical Practice Guideline on the Pharmacological Management of IBS with Constipation. Gastroenterology. 2022;163:118–36. https://doi.org/10.1053/j.gastro.2022.04.016; Lembo A, et al. AGA Clinical Practice Guideline on the Pharmacological Management of IBS with Diarrhea. Gastroenterology. 2022;163:137–51. https://doi.org/10.1053/j.gastro.2022.04.017 [^13]: Nybacka S, et al. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in IBS (CARBIS): a single-centre, single-blind, randomised controlled trial. Lancet Gastroenterology & Hepatology. 2024. https://consensus.app/papers/details/d072075d77935a5d92b4957d77c4e10c/ [^14]: Bertin L, et al. The Role of the FODMAP Diet in IBS. Nutrients. 2024. https://consensus.app/papers/details/e439824aacdc5fc39bb278fabb6ef44b/ [^15]: Van den Houte K, et al. Efficacy and findings of a blinded randomized reintroduction phase for the low FODMAP diet in IBS. Gastroenterology. 2024. https://consensus.app/papers/details/3c36f8c6f72d5ecbbe355b5aab4ca41d/ [^16]: Haghbin H, et al. Efficacy of Dietary Interventions for IBS: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine. 2024. https://consensus.app/papers/details/fe307685b31c589aa8ead2a032c6741c/ [^17]: Rej A, et al. Efficacy and Acceptability of Dietary Therapies in Non-Constipated IBS: A Randomized Trial. Clin Gastroenterol Hepatol. 2022. https://consensus.app/papers/details/d3ddb46a8b7c57a68b9fa0c44a50cc0b/ [^18]: Tetali B, Suresh S (fiber section). Translational Gastroenterology and Hepatology. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11074491/ [^19]: Biesiekierski JR, et al. Review article: exclude or expose? The paradox of conceptually opposite treatments for IBS. Alimentary Pharmacology & Therapeutics. 2022. https://consensus.app/papers/details/3912d79118d8529dadfa5554bb827046/ [^20]: Busam JA, et al. The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025. https://doi.org/10.14309/ajg.0000000000003572 (PMC12940625) [^21]: Tunalı V, et al. A Multicenter Randomized Controlled Trial of Microbiome-Based AI-Assisted Personalized Diet vs Low-FODMAP Diet for IBS. Am J Gastroenterol. 2024. https://consensus.app/papers/details/6bb6b8887045513f999cacd275af9e1e/ [^22]: Cara KC, et al. The effects of vitamin D intake and status on symptom severity and quality-of-life in adults with IBS: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2024. https://doi.org/10.1080/10408398.2024.2400603 --- _This handout is for educational purposes only. It does not replace individualized medical advice. Please consult your healthcare provider for diagnosis and treatment decisions. Information is current as of May 2026._